Tempus AI (NASDAQ:TEM) Shares Down 4.6% – Here’s Why

Tempus AI, Inc. (NASDAQ:TEM)’s stock price dropped 4.6% on Wednesday . The company traded as low as $46.61 and last traded at $46.5740. Approximately 3,476,246 shares traded hands during trading, a decline of 36% from the average daily volume of 5,460,660 shares. The stock had previously closed at $48.83.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: ARK Invest (Cathie Wood) trimmed positions in Meta and Nvidia and added to Tempus, signaling renewed institutional demand and attention that can support liquidity and investor interest. Cathie Wood’s ARK sells Meta and Nvidia stocks, buys Tempus AI
• Positive Sentiment: Tempus announced a collaboration with Daiichi Sankyo focused on ADC clinical development, reinforcing commercial partnerships in oncology that support longer‑term revenue and platform use cases. Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
• Positive Sentiment: Analysts maintain constructive views — Tempus has a consensus “Moderate Buy” rating, which may help underwrite investor confidence after recent volatility. Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Coverage pieces (Zacks/Yahoo) highlight a string of 2026 collaborations and strategic initiatives that expand Tempus’s AI/diagnostics reach; these are generally positive but are longer‑term catalysts rather than immediate earnings drivers. Tempus AI Reinforces Market Position With Collaborations in 2026
• Negative Sentiment: Zacks notes the stock is down materially since the last earnings report (about a 12.9% decline), pointing to investor concern about recent results/forward outlook and heightening short‑term selling pressure. Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?
• Negative Sentiment: Technical/volatility pressures: the stock is trading below its 50‑ and 200‑day moving averages and has a high beta, which can amplify downside moves while investors reassess fundamentals and partnership monetization timelines.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TEM. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Morgan Stanley cut their price target on Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Stifel Nicolaus set a $60.00 price objective on Tempus AI in a research note on Wednesday, February 25th. Canaccord Genuity Group reduced their price target on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, December 22nd. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.62.

Tempus AI Trading Down 6.4%

The business’s 50 day moving average price is $55.67 and its two-hundred day moving average price is $69.99. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13. The company has a market capitalization of $7.62 billion, a price-to-earnings ratio of -30.23 and a beta of 5.29.

Insiders Place Their Bets

In related news, CEO Eric P. Lefkofsky sold 166,250 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $58.87, for a total transaction of $9,787,137.50. Following the completion of the transaction, the chief executive officer owned 8,908,283 shares of the company’s stock, valued at $524,430,620.21. This trade represents a 1.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Ryan M. Bartolucci sold 2,902 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $171,363.10. Following the completion of the sale, the chief accounting officer directly owned 41,159 shares of the company’s stock, valued at $2,430,438.95. The trade was a 6.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 402,591 shares of company stock valued at $24,868,936. 26.27% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Tempus AI

Several large investors have recently modified their holdings of the stock. Cranbrook Wealth Management LLC purchased a new stake in Tempus AI during the third quarter valued at about $25,000. JPL Wealth Management LLC acquired a new stake in shares of Tempus AI during the third quarter valued at approximately $26,000. GAMMA Investing LLC acquired a new stake in shares of Tempus AI during the third quarter valued at approximately $28,000. Los Angeles Capital Management LLC purchased a new stake in shares of Tempus AI in the 4th quarter valued at approximately $27,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Tempus AI in the 3rd quarter worth approximately $38,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.